This module uses fundamental data of Inhibikase Therapeutics to approximate its Piotroski F score. Inhibikase Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Inhibikase Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Inhibikase Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Inhibikase Therapeutics Altman Z Score, Inhibikase Therapeutics Correlation, Inhibikase Therapeutics Valuation, as well as analyze Inhibikase Therapeutics Alpha and Beta and Inhibikase Therapeutics Hype Analysis.
At this time, Inhibikase Therapeutics' Short Term Debt is comparatively stable compared to the past year. Debt To Equity is likely to gain to 0.04 in 2024, whereas Short and Long Term Debt is likely to drop slightly above 124.7 K in 2024. At this time, Inhibikase Therapeutics' Income Quality is comparatively stable compared to the past year. EV To Operating Cash Flow is likely to gain to 0.10 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (2.54).
At this time, it appears that Inhibikase Therapeutics' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Inhibikase Therapeutics is to make sure Inhibikase is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Inhibikase Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Inhibikase Therapeutics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Inhibikase Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Inhibikase Therapeutics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
We derive many important indicators used in calculating different scores of Inhibikase Therapeutics from analyzing Inhibikase Therapeutics' financial statements. These drivers represent accounts that assess Inhibikase Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inhibikase Therapeutics' important valuation drivers and their relationship over time.
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibikase Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibikase Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social
About Inhibikase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibikase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibikase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibikase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.